Why Did Pfizer Stop Talking Up This Business?

For questions about this article or underlying research, email help@trefis.com.

Pfizer (PFE) stock trades at 2.8 times sales, against 3.2 for the S&P 500. Even at that discount, shareholders need to understand exactly what they are buying, and the company’s priorities have changed. On its fourth-quarter 2024 call, management said its COVID-19 portfolio would continue to be a predictable and durable contributor. On the November 3, 2026 call, management emphasized other products instead. So what does Pfizer talk up now, and why the change?

Pfizer Now Talks Up Drugs It Launched Or Bought

During the November 3 call, management focused on products Pfizer either launched or acquired, including Padcev, Nurtec and Lorbrena. Management also explained the strategy behind them: Pfizer continues to invest in this group to soften the loss of exclusivity on older drugs over the next several years.

Mentions of COVID-19 served only to illustrate the part of the business moving in reverse. Management highlighted 7% operational growth in sales for Pfizer’s products other than COVID-19, noting that lower revenue from COVID-19 products offset those gains. Sales of the Paxlovid family declined in the quarter. Although the COVID-19 business still generates revenue, it currently holds back Pfizer’s sales growth, and management’s attention has moved to the drugs meant to replace its older ones.

How Big Are Pfizer’s Launched And Acquired Drugs?

During the third quarter of 2026, Pfizer’s launched and acquired products generated $3.8 billion, with management reporting a 32% operational increase in their sales. With Pfizer’s total revenue for the quarter sitting at $16.6 billion, this newer category accounted for nearly a quarter of the business.

The broader totals still reflect the COVID-19 decline. Despite the rapid growth of the newer drugs, Pfizer’s revenue was 0.4% lower than in the third quarter of 2025. Over the twelve months to September, revenue grew 1.3%, a slower pace than the 3.9% posted during the prior twelve months.

Is Pfizer’s Shift Reassuring For Holders?

Mostly, yes. The business management no longer emphasizes is the one that declined in the third quarter, while the drugs receiving their attention are growing. Furthermore, Pfizer raised its full-year 2026 revenue guidance on November 3.

The concern is timing. For 2027, management named the loss of exclusivity on Ibrance and Xtandi in the U.S. as a key factor, alongside international losses for Eliquis that begin at the end of 2026. These losses arrive as Pfizer’s total sales remain roughly flat, with its third-quarter operating margin falling to 30.9% from 33.2% a year earlier. According to management, Pfizer’s leverage ratio ended the quarter at 2.6 times. That figure sits slightly below its 2026 target of 2.7 times, and management expects it to stay around that level, or go modestly higher, while the older drugs lose exclusivity.

The measure to watch is how fast Pfizer’s launched and acquired products grow in its next report, expected in February 2027.

Paid In Pfizer Stock?

Many readers of a Pfizer article work there and own its stock through grants or a purchase plan. When your paycheck and your savings depend on the same company, one bad year can hit both. Our partner advisory firm offers a free strategy review of ways to protect a large company-stock position and sell it down with less tax.

Request A Free Strategy Review

Spot an error or want more like this? Tell us in 10 seconds.